DK1624072T3 - Kit til bestemmelse af aktiviteten af faktor VII-aktiverende protease i proteinopløsninger - Google Patents

Kit til bestemmelse af aktiviteten af faktor VII-aktiverende protease i proteinopløsninger

Info

Publication number
DK1624072T3
DK1624072T3 DK05023845.0T DK05023845T DK1624072T3 DK 1624072 T3 DK1624072 T3 DK 1624072T3 DK 05023845 T DK05023845 T DK 05023845T DK 1624072 T3 DK1624072 T3 DK 1624072T3
Authority
DK
Denmark
Prior art keywords
activity
determining
factor vii
protease
kit
Prior art date
Application number
DK05023845.0T
Other languages
English (en)
Inventor
Jürgen Dr Römisch
Yner Annette Feu
Hans-Arnold Stöhr
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Application granted granted Critical
Publication of DK1624072T3 publication Critical patent/DK1624072T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96447—Factor VII (3.4.21.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/966—Chemistry: molecular biology and microbiology involving an enzyme system with high turnover rate or complement magnified assay, e.g. multi-enzyme systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
DK05023845.0T 1999-06-10 2000-06-02 Kit til bestemmelse af aktiviteten af faktor VII-aktiverende protease i proteinopløsninger DK1624072T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19926531 1999-06-10
DE10023923A DE10023923A1 (de) 1999-06-10 2000-05-17 Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen
EP00111738A EP1059359B1 (de) 1999-06-10 2000-06-02 Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen

Publications (1)

Publication Number Publication Date
DK1624072T3 true DK1624072T3 (da) 2014-06-30

Family

ID=26005695

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05023845.0T DK1624072T3 (da) 1999-06-10 2000-06-02 Kit til bestemmelse af aktiviteten af faktor VII-aktiverende protease i proteinopløsninger

Country Status (10)

Country Link
US (2) US20030124622A1 (da)
EP (2) EP1059359B1 (da)
JP (2) JP4782911B2 (da)
KR (1) KR100788177B1 (da)
AT (1) ATE315100T1 (da)
AU (1) AU782577B2 (da)
CA (1) CA2311479C (da)
DE (2) DE10023923A1 (da)
DK (1) DK1624072T3 (da)
ES (2) ES2251910T3 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19903693A1 (de) * 1998-04-24 1999-10-28 Centeon Pharma Gmbh Protease zur Aktivierung des Gerinnungsfaktors VII
DE10023923A1 (de) * 1999-06-10 2000-12-14 Aventis Behring Gmbh Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen
DE10036641A1 (de) * 2000-07-26 2002-02-14 Aventis Behring Gmbh Monoklonale Antikörper für die den Blutgerinnungsfaktor VII aktivierende Protease (FSAP)und ihre Verwendung
ATE318315T1 (de) 2000-07-26 2006-03-15 Zlb Behring Gmbh Mutanten der den faktor vii aktivierenden protease und nachweisverfahren mit spezifischen antikörpern
DE10238429A1 (de) * 2002-03-19 2003-10-30 Aventis Behring Gmbh Intellect Marburg I Mutante der Faktor VII aktivierenden Protease (FSAP) als Risikofaktor für Atherosklerose
US7153679B2 (en) 2000-07-26 2006-12-26 Aventis Behring Gmbh Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis
DE10148037A1 (de) * 2001-09-28 2003-04-17 Aventis Behring Gmbh Verwendung der den Blutgerinnungsfaktor VII aktivierenden Protease zur Prophylaxe und Therapie von vaso-proliferativen Erkrankungen
DE10205520A1 (de) * 2002-02-08 2003-08-14 Aventis Behring Gmbh Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease
US7473548B2 (en) * 2003-04-25 2009-01-06 Medtronic, Inc. Optical detector for enzyme activation
DE102005026163A1 (de) 2004-08-24 2006-03-02 Dade Behring Marburg Gmbh Gegen den Marburg I Polymorphismus der Faktor VII aktivierenden Protease (FSAP) gerichtete Antikörper, ihre Herstellung und Verwendung
ATE446377T1 (de) 2005-12-22 2009-11-15 Siemens Healthcare Diagnostics Diagnostisches verfahren zur erkennung von trägern der marburg l-variante der faktor vii- aktivierenden protease (fsap) anhand differenzieller modulation der fsap-aktivität
AT504443B1 (de) * 2006-10-19 2008-11-15 Apeiron Biolog Forschungs Und Verfahren zur bestimmung der aktivität von ace2
EP2077119A1 (de) * 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Behandlung von Fibrosen und Lebererkrankungen
EP2333555A1 (de) * 2009-12-09 2011-06-15 Siemens Healthcare Diagnostics Products GmbH Heterogener Gerinnungstest
EP2386652A1 (de) 2010-05-12 2011-11-16 Siemens Healthcare Diagnostics Products GmbH Homogenes Verfahren zur Bestimmung der Plasminogenaktivator-aktivierenden Aktivität der FSAP
EP3486656A1 (en) * 2011-07-07 2019-05-22 DuPont Nutrition Biosciences ApS Assay

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504921A1 (fr) 1981-04-30 1982-11-05 Choay Sa Medicament nouveau constitue par un complexe aprotinine-plasmine et procede de preparation de ce nouveau complexe
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
WO1990003577A1 (en) * 1988-09-30 1990-04-05 The University Of Vermont And State Agricultural College Immunoassays for catalytically-active, serine proteases
JP3055933B2 (ja) 1989-07-20 2000-06-26 アナリティカル・コントロール・システムズ・インコーポレーテッド 改良された安定な凝固対照
JPH04361986A (ja) * 1991-06-11 1992-12-15 Ohbayashi Corp タワークレーンの据付構台
US6159938A (en) * 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
DE19538716A1 (de) * 1995-10-18 1997-04-24 Behringwerke Ag Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa)
US5874256A (en) * 1995-06-06 1999-02-23 Rijks Universiteit Leiden Method for diagnosing an increased risk for thrombosis or a genetic defect causing thrombosis and kit for use with the same
DE19903693A1 (de) 1998-04-24 1999-10-28 Centeon Pharma Gmbh Protease zur Aktivierung des Gerinnungsfaktors VII
DE19937219A1 (de) * 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie
DE10023923A1 (de) 1999-06-10 2000-12-14 Aventis Behring Gmbh Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen
DE19937218A1 (de) * 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie
ATE318315T1 (de) * 2000-07-26 2006-03-15 Zlb Behring Gmbh Mutanten der den faktor vii aktivierenden protease und nachweisverfahren mit spezifischen antikörpern
EP1226829B1 (de) * 2001-01-08 2008-06-11 CSL Behring GmbH Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms
DE10148037A1 (de) * 2001-09-28 2003-04-17 Aventis Behring Gmbh Verwendung der den Blutgerinnungsfaktor VII aktivierenden Protease zur Prophylaxe und Therapie von vaso-proliferativen Erkrankungen
DE10205520A1 (de) * 2002-02-08 2003-08-14 Aventis Behring Gmbh Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease

Also Published As

Publication number Publication date
JP2011103902A (ja) 2011-06-02
DE50012002D1 (de) 2006-03-30
CA2311479A1 (en) 2000-12-10
ATE315100T1 (de) 2006-02-15
EP1059359B1 (de) 2006-01-04
ES2467091T3 (es) 2014-06-11
ES2251910T3 (es) 2006-05-16
EP1059359A3 (de) 2002-08-14
EP1624072A1 (de) 2006-02-08
EP1624072B1 (de) 2014-04-02
AU782577B2 (en) 2005-08-11
US20030124622A1 (en) 2003-07-03
DE10023923A1 (de) 2000-12-14
US20090087864A1 (en) 2009-04-02
KR20010049517A (ko) 2001-06-15
KR100788177B1 (ko) 2007-12-26
JP2001029098A (ja) 2001-02-06
AU3941000A (en) 2000-12-14
JP4782911B2 (ja) 2011-09-28
CA2311479C (en) 2011-05-10
JP4825316B2 (ja) 2011-11-30
EP1059359A2 (de) 2000-12-13
US7892842B2 (en) 2011-02-22

Similar Documents

Publication Publication Date Title
EP1059359A3 (de) Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen
NO20034687L (no) Hemoglobinanalyse
ATE212037T1 (de) Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
IS6515A (is) Fósturstofnfrumurækt prímata, sem laus er við sermi
ATE331025T2 (de) Medium für die protein- und serumfreie zellkultur
FI971777A0 (fi) Katepsiini O2-proteaasi
ES2043612T3 (es) Procedimiento para la determinacion fotometrica de la actividad de proteina c y/o proteina s.
TR200003732T2 (tr) Aminlerin Schiff-bazlı yaklaşımlarının hazırlanmasına yönelik gelişmiş işlem
ATE256651T1 (de) Phenolherstellung
ATE343369T1 (de) Neue verwendung von proteinhydrolysaten
DE69534078D1 (de) Waschmittel enthaltend einen builder und ein enzym mit verzögerter freigabe
JP2001029098A5 (da)
WO2002021133A3 (en) Methods of detecting cancer based on prostasin
DK1400589T3 (da) Fremgangsmåde til påvisning af prokaryotisk DNA
DK0759079T3 (da) DNA der koder precursor for interleukin-1beta-omdannende enzym-beslægtet cysteinproteinase III (ICErel-III)
PT1159448E (pt) Determinacao de formas biologicamente activas de enzimas proteoliticas
DE69924617D1 (de) Immunologische Bestimmung des hydrophoben Lungensurfaktantproteins SP-C
CA2213083A1 (en) Detection of antibody production
DE69426028D1 (de) Reagenz für die enzymatische Bestimmung des Bikarbonatgehalts in Blutserum
FR2828934B1 (fr) Test de l'immunite cellulaire par des peptides fixes sur support solide
DE60119969D1 (de) Nachweis von infektionen durch nachweis von fettsäuren im kopfraum von flüssigkeitsproben
ATE361320T1 (de) Monoklonaler antikörper gegen protein c inhibitor
DK1348761T3 (da) Marburg I mutant af faktor VII aktiverende protease (FSAP) som risikofaktor for arteriel thrombose
KR900001859A (ko) Ldh₁의 분석법
RU96107948A (ru) Способ прогнозирования развития катаракты после антиглаукоматозных операций